1438 companies · 1459 sector slots · 21 sectors · 12 below Rs1000cr and not scanned · long-term lens
Trend Spotlight
Fed rate-hike odds have flipped sharply higher for the Sept 16 FOMC, adding pressure to an already-weak rupee amid Iran-driven oil volatility.
Market-implied odds of a 25bp Fed hike jumped to roughly 57.5% (from 35.4% a day earlier) after a hawkish Warsh speech and a hot CPI print, reversing what had been a cutting bias earlier this year -- driven by energy-cost inflation from the ongoing Iran conflict. USD/INR sits near record-weak levels around 95.64 against this backdrop, even as Brent has pulled back to $104.61 from a $107-109 spike. For a long-term Indian equity holder, a Fed hiking into an energy shock rather than cutting is a genuine change to the global rate/currency backdrop, not noise -- rate-sensitive and import-cost-exposed sectors are the ones to watch as the meeting resolves this week.
GIFT Nifty points to a firmer open; US closed higher and oil eased, but the Sept 16 FOMC decision is the week's key event.
GIFT Nifty was up 0.51% pre-open at 23,575. US markets closed higher Friday (Dow +0.98%, snapping four losing sessions) as oil and yields paused their Iran-conflict-driven surge; Brent eased to $104.61 after touching $107-109. Nothing fresh on the domestic policy calendar -- the RBI held rates in August and meets again only in October -- but the Sept 15-16 FOMC is now live with hike odds risen sharply, and a weak rupee (~95.64/USD) leaves little room for a surprise.
NSE's event calendar could not be read, so no results schedule is shown
for this session.
Market Overview
Index
Close
Points
Change
P/E
P/B
Nifty 50
23,398.10
▼ -79.70
▼ -0.34%
19.78
2.83
Nifty Next 50
72,083.70
▼ -447.20
▼ -0.62%
19.06
3.21
Nifty 500
22,866.50
▼ -85.85
▼ -0.37%
22.16
3.18
Nifty Bank
56,606.55
▲ +134.60
▲ +0.24%
13.39
1.70
NIFTY Midcap 100
62,197.20
▼ -160.15
▼ -0.26%
29.98
4.28
▲ 952 advancing■ 40 unchanged▼ 1639 decliningof 2631 equities, vs the 2026-09-10 close
Cash market, ₹ crore
FII / FPI net
▼ -930.90
bought 12,617 · sold 13,548
DII net
▲ +1,968.17
bought 15,110 · sold 13,141
FII / FPI
DII
Source: NSE ind_close_all_20260911
(levels, index P/E and P/B) and the full-market bhavcopy (breadth).
Index P/E from NSE's official daily index file.
Since We Flagged
The desk's track record — the FIRST call made on each standing name,
against its call today. Entry price is the close on the day of that first call, read
from the cached bhavcopy for that date. "Unchanged" means the original call still
stands.
Hyundai India's Q1 profit fall looks transitory, not structural Automobiles
Hyundai India's MD/CEO said production at the fire-affected Chennai plant has fully normalized and reiterated FY27 guidance of 8-10% volume growth and 11-14% EBITDA margin, supporting the view that the Q1 FY27 35% profit decline was a one-off from the May 2026 Mobis supplier fire rather than a structural franchise issue. Actual Q2 results are not yet out, so this is supportive, not conclusive, evidence.
IOL Chemicals' Q1 results back its capex thesis despite the recent price drop Pharmaceuticals
IOL Chemicals posted 37% YoY revenue growth and an 89.9% PAT surge in Q1 FY27, with non-ibuprofen pharma revenue now 43% of the pharma mix (up from 36%) -- evidence the Rs 495 crore capex plan is converting into growth. A GMP certificate for the new Hungary-inspected CDMO facility and a fresh US FDA nod for its ibuprofen plant add supporting milestones. No company-specific negative catalyst was found to explain the session's -8.10% price move.
Brigade's Chennai EC revocation looks contained so far, but litigation is still live Realty
No further environmental-clearance issues or stop-work orders have surfaced at any other Brigade project since the Morgan Heights (Perumbakkam) revocation, and Brigade is contesting the SEIAA order in the Supreme Court. Sector sentiment has otherwise turned sharply positive, but that improvement -- and a 20% intraday jump in Brigade shares -- is tied to an unrelated Rs 214.71 crore preferential warrant issue to Minerva Ventures Fund, not resolution of the EC matter.
Pine Labs raised FY27 guidance despite a weak Q1 print, but analysts aren't confirming an upgrade yet Financial Services
Pine Labs' Q1 FY27 profit fell 67% QoQ and shares slid on the print, even as management raised FY27 revenue-growth guidance to 21-23.5% and lifted margin guidance. Citi, Morgan Stanley and Emkay all cut price targets while holding their existing ratings -- none moved to an outright positive call, which reads as mixed evidence against the pending AVOID->HOLD confirmation, not for it.
DOMS: the pullback is real but the stock still isn't cheap, and margins just took a hit Retail & Consumer
DOMS is down roughly 29% from its all-time high, but at ~58-59x trailing earnings it is still priced for uninterrupted high-teens growth, and Q1 FY27 EBITDA margin fell to 12.3% from 17.6% on West Asia-linked input inflation. Management calls this the margin trough and has reiterated 18-20% FY27 revenue guidance and a 16-17% FY28 margin target, but that is unproven. Separately, co-promoter FILA has sold down its DOMS stake twice in 18 months, cutting combined promoter holding from 70.4% to 63.4% in a year -- framed as parent-level deleveraging, but worth tracking.
Entry score is 40% cheap-vs-history + 25% quality trend + 15% technicals, renormalised over those three — the 20% news catalyst is not counted because no research was written for this session. It is not treated as neutral; it is absent. ≥62 accumulate · 45–61 watch · <45 avoid.
Source: data/verdicts.json × NSE sector index closes.
Stocks to Watch
Split evenly across large/mid/small/micro cap so this list isn't one
tier's picks — new calls first, then the highest long-term composites within each.
Micro-cap names are boxed and flagged Highly Volatile — worth
watching, not a call to buy — since their price swings run about twice every other
tier's. Each card shows the figures that selected it — open the desk for the full
six-lens panel.